Abstract 403P
Background
The use of ALK inhibitors is one of the success stories in the precision medicine for treating advanced ALK-positive non-small cell lung cancer (NSCLC). However, the developing countries have significant cost constraints in using ALK inhibitors. The primary objective of this study was to investigate the treatment patterns and outcomes in Indian ALK-positive NSCLC patients.
Methods
An audit of a prospectively collected database of advanced ALK-positive NSCLC patients treated from Jan 2013 to Dec 2017 was conducted. Patients were divided into those who received ALK inhibitor in first-line (including upfront strategy, or after a few chemotherapy cycles), or who did not receive ALK inhibitor in the first line. SPSS version 20.0 was used for statistical analysis.
Results
A total of 461 patients were available for analysis, 62.5% were males, median age 50 years (range 19-75) and 78.3% had ECOG PS 0-1. 169 (36.7%) patients were started on crizotinib upfront, 232 (50.3%) on chemotherapy, 12 (2.6%) received second/third-generation ALK inhibitors, and 22 (4.8%) patients were offered best supportive care. The main reasons for not starting crizotinib upfront included patients not willing to wait for the report (49.6%), financial constraints (21.3%), and symptomatic patients needing early initiation of therapy (13.3%). 78 (16.9%) patients were shifted to crizotinib after 1-2 cycles and 38 (8.2%) after 4-6 cycles of chemotherapy. The median progression-free survival on first-line therapy for the entire cohort was 14.1 months (m) (95% CI: 12.2-15.9), with a significant difference between patients receiving ALK inhibitor in first-line in any strategy vs. not in first-line [17.8 m (95% CI:14.9-20.8) vs. 5.9 m (95% CI:4.2-7.7), p<0.001). The median overall survival was 29.8 m (95% CI: 24.8-34.8), with 37.7 m (95% CI: 28.5-46.9) for ALK inhibitor in first-line vs. 20.2 m (95% CI: 15.6-24.7) for not in first-line (p<0.001). 295 (63.1%) received crizotinib completely free via various extramural support schemes.
Conclusions
A majority of our ALK-positive NSCLC patients were exposed to crizotinib through various support mechanisms. Those patients who could receive ALK inhibitors in the first-line had a significant survival advantage.
Clinical trial identification
CTRI/2013/01/003335.
Editorial acknowledgement
Legal entity responsible for the study
Tata Memorial Hospital, Mumbai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session